PBB3 Imaging in Parkinsonian disorders: evidence for binding to abnormally aggregated proteins in addition to tau proteins
Objective: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 ([11C]methylamino pyridin-3-yl buta-1,3-dienyl benzo[d]thiazol-6-ol) in tauopathies, and in conditions not…Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study
Objective: This study was designed to detect whether in Parkinson’s disease (PD) the putaminal serotonin–over–dopamine transporter ratio has a threshold that is critical for the…Longitudinal AV-1451 PET imaging in Progressive Supranuclear Palsy and Cortico-Basal Syndrome
Objective: To evaluate change in AV-1451 positron emission tomography (PET) imaging in patients with Progressive Supranuclear Palsy (PSP) and Cortico-Basal Syndrome (CBS) over 9 months…18F-AV-1451 PET imaging in pre-dementia Parkinson’s disease
Objective: To describe cortical and subcortical 18F-AV-1451 binding in Parkinson’s disease patients with and without mild cognitive impairment (PD-MCI and PD-nonMCI). Background: The radioligand 18F-AV-1451…Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations
Objective: To assess phosphodiesterase 10A (PDE10A) expression in vivo, using [11C]IMA107 PET in patients with PDE10A and adenylate cyclase 5 (ADYC5) mutations. Background: Cyclic adenosine…Serotonergic, Dopaminergic Disruptions and Related Non-Motor Features Throughout the Course of Parkinson’s Disease: A Transversal PET Study
Objective: To explore the progression of DA and 5-HT lesions during the course of Parkinson’s disease (PD) and their respective contribution to the pathogenesis of…Neuroimaging studies in familial forms of Parkinson’s disease: A systematic review
Objective: We aim to systematically review the current status of MRI, PET and SPECT imaging in asymptomatic (aPD) and symptomatic (sPD) genetic carriers of PD.…In vivo mapping of nigro-striatal dopamine transporter (DAT) availability in early Parkinson´s disease patients using [18F]FE-PE2I and high-resolution positron emission tomography.
Objective: The objective of the present work was to evaluate in vivo with high resolution positron emission tomography (PET), the relative loss of the dopamine…[11C]PK11195 PET in Alzheimer’s disease and progressive supranuclear palsy: the NIMROD study
Objective: Here we test whether the intensity and regional distribution of neuro-inflammation differs between Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP) and controls; and whether neuro-inflammation…Absence of depression in de novo Parkinson’s disease: a benign motor phenotype?
Objective: This study aimed to assess the impact of early depression on motor deficits relative to the level of striatal dopaminergic depletion in patients with…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 40
- Next Page »